原发性性腺功能减退症是睾丸癌幸存者的一种公认的并发症。然而，抑制下丘脑-垂体轴的其他原因也可能导致继发性性腺功能减退症，包括肥胖、高剂量糖皮质激素、慢性终末器官衰竭和糖尿病。本研究的目的是探讨澳大利亚睾丸癌幸存者的低血清总睾酮水平，并检查其与体重指数、年龄和既往化疗使用的关系。临床数据包括身高、体重、诊断、治疗和随访期间的激素评估。以上数据摘自澳大利亚和新西兰泌尿生殖和前列腺 (ANZUP) 癌症试验组 Chemocog 研究（2007-2012 年），并附有来自 iTestis 睾丸癌登记处的两个澳大利亚高容量睾丸癌中心的数据（2012-2019 年） ）。低睾酮水平定义为睾酮（T）血清浓度 < 10 nmol/L，血清黄体生成素（LH）浓度 > 8 IU/L定义为原发性，否则为继发性。285个个体患有 1 期或晚期睾丸癌的患者也被包括在内。其中 105 例 (37%) 接受了睾丸切除术和化疗。随访期间，49 人 (17%) 符合低睾酮标准：21 人 (43%) 为原发性低睾酮，27 人 (55%) 为继发性低睾酮。体重指数较高的睾丸癌幸存者更有可能表现出低睾酮水平，包括原发性（p = 0.032）和继发性（p = 0.028）。我们的数据没有显示我们的队列中年龄较大或化疗使用与低睾酮之间存在关联的证据。血清总睾酮水平低在睾丸癌幸存者中很常见，并且与睾丸切除术前较高的体重指数相关，这表明睾酮水平升高质量指数可能导致该人群睾酮水平较低，睾丸癌随访中应考虑体重、饮食和运动。© 2024。作者。

Primary hypogonadism is a recognised complication in survivors of testicular cancer. However, secondary hypogonadism can result from other causes that suppress the hypothalamic-pituitary axis, including obesity, high dose glucocorticoids, chronic end organ failure, and diabetes. The aim of this study was to explore low total serum testosterone in Australian survivors of testicular cancer and examine associations with body mass index, age, and prior chemotherapy use.Clinical data including height, weight, diagnosis, treatment, and hormonal evaluations during follow-up were extracted from the Australian and New Zealand Urogenital and Prostate (ANZUP) Cancer Trials Group Chemocog study (2007-2012), accompanied by data from two Australian, high-volume testicular cancer centres included in the iTestis testicular cancer registry (2012-2019). Low testosterone was defined by a serum concentration of testosterone (T) < 10 nmol/L, and was classified as primary by a serum concentration of luteinising hormone (LH) > 8 IU/L, otherwise as secondary.Two hundred eighty-five individuals with either stage 1 or advanced testicular cancer were included. Of these, 105 (37%) were treated with orchidectomy and chemotherapy. Forty-nine (17%) met criteria for low testosterone during follow-up: 21 (43%) had primary and 27 (55%) had secondary low testosterone. Survivors of testicular cancer with higher body mass index were more likely to display low testosterone, both primary (p = 0.032) and secondary (p = 0.028). Our data did not show evidence of an association between older age or chemotherapy use and low testosterone in our cohort.Low total serum testosterone was common in survivors of testicular cancer, and associated with a higher body mass index prior to orchidectomy, suggesting that elevated body mass index may contribute to low testosterone in this population, and that body weight, diet, and exercise should be addressed in testicular cancer follow-up.© 2024. The Author(s).